Sutro Biopharma (STRO) - Total Assets
Based on the latest financial reports, Sutro Biopharma (STRO) holds total assets worth $209.66 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See STRO net assets for net asset value and shareholders' equity analysis.
Sutro Biopharma - Total Assets Trend (2016–2024)
This chart illustrates how Sutro Biopharma's total assets have evolved over time, based on quarterly financial data.
Sutro Biopharma - Asset Composition Analysis
Current Asset Composition (December 2024)
Sutro Biopharma's total assets of $209.66 Million consist of 88.7% current assets and 11.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 49.2% |
| Accounts Receivable | $8.62 Million | 2.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Sutro Biopharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Sutro Biopharma.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sutro Biopharma's current assets represent 88.7% of total assets in 2024, an increase from 71.7% in 2016.
- Cash Position: Cash and equivalents constituted 49.2% of total assets in 2024, up from 16.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 2.2% of total assets.
Sutro Biopharma Competitors by Total Assets
Key competitors of Sutro Biopharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sutro Biopharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.53 | 3.09 | 12.78 |
| Quick Ratio | 2.53 | 3.09 | 12.78 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $110.22 Million | $274.49 Million | $348.58 Million |
Sutro Biopharma - Advanced Valuation Insights
This section examines the relationship between Sutro Biopharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.11 |
| Latest Market Cap to Assets Ratio | 0.20 |
| Asset Growth Rate (YoY) | -17.7% |
| Total Assets | $387.21 Million |
| Market Capitalization | $79.09 Million USD |
Valuation Analysis
Below Book Valuation: The market values Sutro Biopharma's assets below their book value (0.20x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Sutro Biopharma's assets decreased by 17.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sutro Biopharma (2016–2024)
The table below shows the annual total assets of Sutro Biopharma from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $387.21 Million | -17.74% |
| 2023-12-31 | $470.74 Million | +15.68% |
| 2022-12-31 | $406.94 Million | +19.20% |
| 2021-12-31 | $341.41 Million | -13.37% |
| 2020-12-31 | $394.11 Million | +152.04% |
| 2019-12-31 | $156.37 Million | -29.92% |
| 2018-12-31 | $223.14 Million | +447.33% |
| 2017-12-31 | $40.77 Million | -41.15% |
| 2016-12-31 | $69.28 Million | -- |
About Sutro Biopharma
Sutro Biopharma, Inc. operates as a oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid … Read more